Skip to content
Review Open access

Non-Traditional Antibacterial Agents Relevant to the WHO 2024 Priority Pathogens: A Structured Update of the Clinical Pipeline

Sep 2026 · Antibiotics · Vol 15, pp. 899 · 0 citations · 100 references
Medicine

TL;DR

The pipeline is dominated by bacteriophages and markedly skewed toward carbapenem-resistant Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), with few or no candidates targeting carbapenem-resistant Acinetobacter baumannii (CRAB), Shigella or Salmonella.

Abstract

Background/Objectives: Antimicrobial resistance (AMR) is an urgent global threat, with bacteria developing resistance against most antibiotics currently in clinical use. Non-traditional antibacterials—including bacteriophages, antimicrobial peptides (AMPs), monoclonal antibodies (mAbs), live biotherapeutic products (LBPs) and anti-virulence small molecules—act through mechanisms distinct from traditional antibiotics and may exhibit mechanism-dependent differences in the propensity for resistance development. Despite growing interest, the landscape of non-traditional candidates in active clinical development against WHO priority pathogens has not been recently systematically mapped. This review aimed to characterize the current non-traditional antibacterial clinical pipeline targeting pathogens on the WHO Bacterial Priority Pathogens List (BPPL) 2024. Methods: Candidates were identified from the WHO antibacterial clinical pipeline report (October 2025) and verified through the Global AMR R&D Hub, ClinicalTrials.gov, and targeted searches of peer-reviewed publications, conference abstracts, and company communications. Candidates were included if they showed documented clinical activity since January 2023. Results: Twenty-seven candidates met the inclusion criteria, of which 20 remain in active clinical development and seven have been discontinued or paused or have unverified status. The pipeline is dominated by bacteriophages and markedly skewed toward carbapenem-resistant Pseudomonas aeruginosa (CRPA) and methicillin-resistant Staphylococcus aureus (MRSA), with few or no candidates targeting carbapenem-resistant Acinetobacter baumannii (CRAB), Shigella or Salmonella. Conclusions: Non-traditional antibacterials represent a promising but underfunded and unevenly distributed pipeline—with public and philanthropic investment in antibacterial R&D totaling just $2.51 billion across 2017–2023, a seven-year total, against an estimated $251–276 billion in global pharmaceutical R&D spending in a single recent year. Realizing their potential will require substantially greater investment and more deliberate prioritization toward the WHO priority pathogens currently underserved by the non-traditional pipeline.

Read PDF

Similar papers

Review Sep 2026

Animal-Derived Antimicrobial Peptides: Emerging Therapeutic Strategies against Multidrug-Resistant Pathogens.

It is argued that the realistic near-term contribution of animal-derived AMPs lies in combination therapy with existing antibiotics and in topical or localised indications with direct clinical evidence, while their use as stand-alone systemic agents remains a preclinical and early-clinical prospect rather than an estab...

Mallu Mallikarjuna, Narasimha Golla · 0 citations
Review Sep 2026

Non-antibiotic therapeutic approaches for antimicrobial resistance: current evidence and future directions

This review summarizes the current evidence on non-antibiotic therapeutics including bacteriophages, antimicrobial peptides, anti-virulence agents, monoclonal antibodies, microbiome-based therapies, CRISPR-Cas systems, nanoparticles, photodynamic therapy, repurposed non-antibiotic drugs and combination strategies.

B. Ganesan, A. Mishra, D. Hota et al. · 0 citations
Review Open access Oct 2026

Novel Antibiotics Approved by the FDA (2022–2025)

Antimicrobial resistance (AMR) is a growing global health crisis, emphasizing the urgent need for new antibiotics. Despite high costs and long development timelines, several novel antibiotics were approved by the U.S. Food and Drug Administration (FDA) between 2022 and 2025. This review summarizes the antibiotic discov...

M. Shahrokhi, Rheanna E. Walther · 0 citations
Review Oct 2026

Combating Antimicrobial Resistance: Emerging Non-Traditional Therapeutics, Clinical Translation Challenges, and Future Perspectives.

Antimicrobial resistance (AMR) has emerged as one of the most severe global health threats. The rapid expansion of multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens compromises the effectiveness of conventional antibiotics. Globally, ESKAPE organisms (Enterococcus faecium, Staphylococcus aureus,...

Zahra Shareef, H. I. Hussain, A. Aqib et al. · 0 citations
Review Open access Oct 2026

Structural innovation and therapeutic potential of oxazolidinone antibacterials

Background: Oxazolidinones mark a major advance in antibacterial therapy, being the first new antibiotic class introduced into hospitals in over three decades. Their relevance is underscored by the global crisis of antimicrobial resistance (AMR), particularly against multidrug‑resistant Gram‑positive pathogens. Methodo...

Gopal Krishna Padhy, J. Panda, Deepankar Rath · 0 citations
Review Open access Oct 2026

Beyond Antibiotics: Emerging Therapeutic Strategies, Innovations, and Sustainable Pathways to Combat Antimicrobial Resistance in the 21st Century

Antimicrobial resistance (AMR) is a major global health threat that erodes the effectiveness of antibiotics and increases morbidity, mortality, and healthcare costs. Updated forecasts project that bacterial AMR could directly cause approximately 39 million deaths between 2025 and 2050, with annual deaths rising from 1....

P. Ashinze, Oluwadamilare Olatunbosun, Aditya Gaur et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.